Table 3.
Antimicrobial activities of buforin II, substituted analogs, designed synthetic analogs, and magainin II
| Microorganism | Minimal inhibitory concentration, μg/ml
|
|||||||
|---|---|---|---|---|---|---|---|---|
| BUF II | [L7] BUF(5–21) | [K2][K6][L7] BUF(5–21) | [RLLR]5 | [RVHRLLR]3 | BUF(5–13) [RLLR]3 | BUF(5–13) MG(1–14) | Magainin II | |
| Gram-positive bacteria | ||||||||
| Bacillus subtilis | 2 | 32 | 16 | 2 | 8 | 1 | 16 | 50 |
| Staphylococcus aureus | 4 | 32 | 16 | 1 | 64 | 1 | 16 | 50 |
| Streptococcus mutans | 2 | 32 | 32 | 2 | 32 | 0.5 | 16 | 100 |
| Streptococcus pneumoniae | 4 | 32 | 16 | 2 | 128 | 1 | 16 | 50 |
| Gram-negative bacteria | ||||||||
| Escherichia coli | 4 | 32 | 16 | 2 | 128 | 1 | 16 | 100 |
| Salmonella typhimurium | 1 | 16 | 4 | 1 | 4 | 1 | 8 | 25 |
| Serratia marcescens | 4 | 64 | 32 | 2 | 64 | 1 | 16 | 50 |
| Pseudomonas putida | 2 | 16 | 16 | 2 | 64 | 2 | 32 | 50 |
| Fungi | ||||||||
| Candida albicans | 1 | 16 | 16 | 8 | >256 | 2 | 4 | 25 |
| Cryptococcus neoformans | 1 | 16 | 8 | 8 | 128 | 1 | 4 | 12 |
| Saccharomyces cerevisiae | 1 | 16 | 4 | 8 | >256 | 4 | 4 | 25 |
Minimal inhibitory concentrations were the average values obtained in triplicates on three independent measurements.